Pure Global AI
NCT06379893Recruiting

A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain

A Prospective Real-World Evidence Study Evaluating the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis (OA) Pain
HALEONPhase 4ClinicalTrials.govdrug
Study focus
Disease/Condition
Pain
Drug/Device/Intervention
Voltaren Gel 1% (diclofenac sodium) (US only)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
HALEON
Location
Marrero,San Antonio,Bydgoszcz,Chojnice,Katowice,Malbork,Ostróda,Łódź, Poland,United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Apr 25, 2024
End date
Nov 15, 2024
Enrollment
195 participants
Primary outcome

Change from Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1,Change from Baseline in the Average Minutes of MVPA at Week 2,Change from Baseline in the Average Minutes of MVPA at Week 3

Summary

The purpose of this study is to investigate how topical diclofenac use can improve functional
 mobility and physical activity primarily, as well as other quality-of-life (QoL) parameters
 such as sleep, mood, and engagement in daily activities in participants with knee OA.

ICD-10 classifications
Pain, unspecifiedPain, not elsewhere classifiedPain in limbAcute painOther chronic pain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06379893
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06379893 through Pure Global AI's free database. This Phase 4 trial is sponsored by HALEON and is currently Recruiting. The study focuses on Pain. Target enrollment is 195 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.